Clinical Scenario: Treatment Selection in the third line and beyond in cGVHD

EP: 1.Differentiating Acute and Chronic Graft-vs-Host Disease

EP: 2.Navigating Chronic GVHD: Phases of Pathophysiology and Best Practices in Patient Monitoring

EP: 3.Optimizing Chronic GVHD Therapy

EP: 4.Navigating Treatment Decisions in Chronic GVHD

EP: 5.Overview of Advanced Therapies in cGVHD

EP: 6.Overview of the ROCKstar Study

EP: 7.Considerations for Third-Line Treatment in Chronic GVHD

Now Viewing

EP: 8.Clinical Scenario: Treatment Selection in the third line and beyond in cGVHD

EP: 9.Recent Updates: REACH3, ROCKstar, and RWD

EP: 10.AGAVE-201: Axatilimab for cGVHD

EP: 11.Emerging Trends in Chronic GVHD: Promising Clinical Trials and the Future Treatment Landscape

EP: 12.Clinical Impact of Patient-Reported Outcomes in cGVHD

EP: 13.Multidisciplinary Approaches to GVHD

Video content above is prompted by the following:

Dr Holtan: Please read this clinical scenario: Four months after having undergone allogenic hematopoietic stem transplant, a patient presents to the clinic with rashes over a large portion of his body and dry eyes. Based on clinical presentation and lab results, a diagnosis of moderate cGVHD is established. Patient was treated with steroids and subsequent calcineurin inhibitors for 4 to 6 weeks but showed little improvement in cGVHD symptoms.

• Dr Ali:What other treatments could be used in such patients once steroid refractoriness is established?
  • Are there factors you consider when choosing an alternate treatment option (efficacy, safety profile, clinical manifestations)?